


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A pharmaceutical composition for the treatment of chronic obstructive pulmonary disease comprising:

(a) one or more anticholinergics of formula 1



wherein:

X- is an anion with a single negative charge,

or an enantiomer, mixture of enantiomers, racemate, solvate, or hydrate thereof; and

(b) one or more NK₁ receptor antagonists,

or an enantiomer, mixture of enantiomers, racemate, solvate, or hydrate thereof.


2. (Previously Presented) The pharmaceutical composition according to claim 1, wherein X⁻ is chloride, bromide, iodide, sulphate, phosphate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, 4-toluenesulphonate, or methanesulphonate.

3. (Previously Presented) The pharmaceutical composition according to claim 1, wherein X⁻ is bromide.

4. (Currently Amended) The pharmaceutical composition according to claim 1, wherein the NK₁ receptor antagonists are selected from among BHF-1149 (S)-N-[2-[3,5-bis(trifluoromethyl) phenyl]ethyl]-4-(cyclopropylmethyl)-N-methyl-α-phenyl-1-piperazineacetamide, CP-122721 (+)-(2S, 3S)-3-(2-methoxy-5-


trifluoromethoxybenzyl)amino-2-phenylpiperidine, **FK-888** (4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-pyrrol-2-yl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide, **NKP-608C**, **NKP-608A** (2R,4S)-N-[1-{3,5-bis(trifluoromethyl)-benzoyl}-2-(4-chlorobenzyl)-4-piperidinyl]-quinoline-4-carboxamide, **CGP-60829**, **SR-140333** (S)-1-[2-{3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)piperidin-3-yl}ethyl]-4-phenyl-1-azabicyclo[2.2.2]octane, **LY-303870** (R)-1[N-(2-methoxybenzyl)acetyl]amino]-3-(1H-indol-3-yl)-2-[N-(2-(4-(piperidinyl)piperidin-1-yl)acetyl)amino]propane, **MEN-11420**, **SB-223412** (S)-(-)-N(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide, **MDL-105172A** 1-(3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)-3-pyrrolidinyl)-4-phenylpiperidin-morpholinecarboxamide, **MDL-103896**, **MEN-11149** 2-(2-naphthyl)-1-N-[(1R,2S)-2-N-[2-(H)indol-3-ylcarbonyl]aminocyclohexanecarbonyl]-1-[N'-ethyl-N'-(4-methylphenylacetyl)]diaminoethane, **MEN-11467** (1R,2S)-2-N[1(H)indol-3-yl-carbonyl]-1-N-[N(p-tolylacetyl)-N-D-3-(2-naphthyl)alanyl]diaminocyclohexane, **DNK-333A**, **SR-144190** (R)-3-[1-[2-(4-benzoyl)-2-(3,4-difluorophenyl)-morpholin-2-yl]ethyl]-4-phenylpiperidin-4-yl)-1-dimethylurea, **YM-49244**, **YM-44778**, **ZM-274773** N-[2(S)-(3,4-dichlorophenyl)-4-[4-(2-oxoperhydropyrimidin-1-yl)piperidin-1-yl]butyl]-N-methylbenzamide dihydrochloride, **MEN-10930**, **S-19752**, Neuronorm, **YM-35375** N-(2-(3,4-dichlorophenyl)-4-(spiro(isobenzofuran-1(3H),4'-piperidin-1'-yl)butyl)-N-methylbenzamide, **DA-5018**, **MK-869**, **L-754030** 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, **CJ-11974** (2S,3S-cis)-2-diphenylmethyl)-N-1-azabicyclo[2.2.2]octan-3-amine, **L-758298** [3-[[2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-morpholin-4-yl]methyl]-4,5-dihydro-5-oxo-1H-1,2,4-triazole-1-phosphonic acid bis(N-methyl-D-glucamine) salt, **DNK-33A**, **CJ-11974**, **TAK-637** (aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione, **GR-205171** (2S,3S)-N-[2-methoxy-5-[5-(trifluoromethyl)-1-tetrazolyl]benzyl]-N-(2-phenylpiperidin-3-yl)amine dihydrochloride, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-[(3-hydroxy-propyl)-methyl-amino]-piperidin-1-yl]-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-piperidin-1-yl]-N-methyl-2-phenylacetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(cyclopropylmethyl-methyl-amino)-piperidin-1-yl]-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2--{4-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-

piperidin-1-yl}-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[cyclopropylmethyl-(3-hydroxy-propyl)-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide, or an arylglycinamide compound of formula 3



wherein:

R¹ and R² together with the N to which they are bound form a ring of formula




wherein r and s are each 2 or 3;

R⁶ is H, -C₁-C₅-alkyl, C₃-C₅-alkenyl, propynyl, hydroxy(C₂-C₄)alkyl, methoxy(C₂-C₄)alkyl, di(C₁-C₃)alkylamino(C₂-C₄)alkyl, amino(C₂-C₄)alkyl, amino, di(C₁-C₃)alkylamino, monofluoro- to perfluoro(C₁-C₂)alkyl, N-methylpiperidinyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl,

R⁷ is one of (a) to (d),

(a) hydroxy

(b) 4-piperidinopiperidyl,



wherein R¹⁶ and R¹⁷ are each independently H, (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl, hydroxy(C₂-C₄)alkyl, dihydroxy(C₂-C₄)alkyl, (C₁-C₃)alkoxy(C₂-C₄)alkyl, phenyl(C₁-C₄)alkyl or di(C₁-C₃)alkylamino(C₂-C₄)alkyl, and


R⁸ is H,

or an enantiomer, mixture of enantiomers, or racemate thereof.


5. (Currently Amended) The pharmaceutical composition according to claim 1, wherein the NK₁ receptor antagonists are selected from the group consisting of BHFF-1149 (*S*)-N-[2-[3,5-bis(trifluoromethyl) phenyl]ethyl]-4-(cyclopropylmethyl)-N-methyl-α-phenyl-1-piperazineacetamide, CP-122721 (+)-(2*S*, 3*S*)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine, CGP-60829, MK-869, CJ-11974 (2*S*,3*S*-*cis*)-2-diphenylmethyl)-N-1-azabicyclo-[2.2.2]octan-3-amine, GR-205171 (2*S*,3*S*)-N-[2-methoxy-5-[5-(trifluoromethyl)-1-tetrazolyl]benzyl]-N-(2-phenylpiperidin-3-yl)amine dihydrochloride, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[(3-hydroxy-propyl)-methyl-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-piperidin-1-yl]-N-methyl-2-phenylacetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(cyclopropylmethyl-methyl-amino)-piperidin-1-yl]-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide, N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-{4-[cyclopropylmethyl-(3-hydroxy-propyl)-amino]-piperidin-1-yl}-N-methyl-2-phenyl-acetamide, or an arylglycinamide compound of formula 3

wherein:

R¹ and R² together with the N to which they are bound form a ring of formula



wherein s is 2 or 3;



wherein R¹⁶ and R¹⁷ are each independently H, (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl, hydroxy(C₂-C₄)alkyl, dihydroxy(C₂-C₄)alkyl, (C₁-C₃)alkoxy(C₂-C₄)alkyl, phenyl(C₁-C₄)alkyl or di(C₁-C₃)alkylamino(C₂-C₄)alkyl, and

R⁸ is H,

or an enantiomer, mixture of enantiomers, or racemate thereof.

6. (Previously Presented) The pharmaceutical compositions according to one of claim 1, wherein the NK₁ receptor antagonist is (S)-N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-piperidin-1-yl]-N-methyl-2-phenylacetamide or an acid addition salt thereof.

7. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the weight ratio of the anticholinergic to the NK₁ receptor antagonist is in the range from 1:100 to 100:1.

8. (Previously Presented) The pharmaceutical composition according to claim 1, wherein a single administration corresponds to a dosage of the combination of the anticholinergic and the NK₁ receptor antagonist of 0.01 to 10,000 µg.

9. (Withdrawn) The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is in the form of a formulation suitable for inhalation.

10. (Withdrawn) The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is a formulation selected from among inhalable powders, propellant-containing metering aerosols and propellant-free inhalable solutions or suspensions.

11. (Withdrawn) The pharmaceutical composition according to claim 10, wherein the pharmaceutical composition is an inhalable powder which contains the anticholinergic and

the NK₁ receptor antagonist in admixture with suitable physiologically acceptable excipients selected from the monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, or mixtures of these excipients.

12. (Withdrawn) The inhalable powder according to claim 11, wherein the excipient has a maximum average particle size of up to 250 μ m.

13. (Withdrawn) A capsule containing an inhalable powder according to claim 11 or 12.

14. (Withdrawn) The pharmaceutical composition according to claim 10, wherein the pharmaceutical composition is an inhalable powder consisting essentially of the anticholinergic and the NK₁ receptor antagonist.

15. (Withdrawn) The pharmaceutical composition according to claim 10, wherein the pharmaceutical composition is a propellant-containing inhalable aerosol comprising the anticholinergic and the NK₁ receptor antagonist in dissolved or dispersed form.

16. (Withdrawn) The propellant-containing inhalable aerosol according to claim 15, wherein the propellant gas is n-propane, n-butane or isobutane, or chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane, or cyclobutane.

17. (Withdrawn) The propellant-containing inhalable aerosol according to claim 16, wherein the propellant gas is TG11, TG12, TG134a, TG227 or a mixture thereof.

18. (Withdrawn) The propellant-containing inhalable aerosol according to claim 15, further comprising one or more other ingredients selected from the group consisting of cosolvents, stabilizers, surfactants, antioxidants, lubricants and means for adjusting the pH.

19. (Withdrawn) The propellant-containing inhalable aerosol according to claim 15, wherein the inhalable aerosol contains up to 5 wt.-% of the anticholinergic and/or the NK₁ receptor antagonist.

20. **(Withdrawn)** The pharmaceutical composition according to claim 10, wherein the pharmaceutical composition is a propellant-free inhalable solution or suspension which contains water, ethanol or a mixture of water and ethanol as solvent.
21. **(Withdrawn)** The inhalable solution or suspension according to claim 20, wherein the pH is 2-7.
22. **(Withdrawn)** The inhalable solution or suspension according to claim 21, wherein the pH is adjusted by means of an acid selected from among hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid or a mixture thereof.
23. **(Withdrawn)** The inhalable solution or suspension according to claim 20, further comprising other co-solvents and/or excipients.
24. **(Withdrawn)** The inhalable solution or suspension according to claim 23, wherein the co-solvents are isopropyl alcohol, propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols or polyoxyethylene fatty acid esters.
25. **(Withdrawn)** The inhalable solution or suspension according to claim 23, wherein the excipients are surfactants, stabilizers, complexing agents, antioxidants and/or preservatives, flavorings, pharmacologically acceptable salts and/or vitamins.
26. **(Withdrawn)** The inhalable solution or suspension according to claim 25, wherein the complexing agent is editic acid or a salt of editic acid.
27. **(Withdrawn)** The inhalable solution or suspension according to claim 25, wherein the antioxidants are ascorbic acid, vitamin A, vitamin E, or tocopherols.
28. **(Withdrawn)** The inhalable solution or suspension according to claim 25, wherein

the preservatives are cetyl pyridinium chloride, benzalkonium chloride, benzoic acid, or benzoates.

29. (Withdrawn) The inhalable solution or suspension according to claim 23, consisting essentially of the anticholinergic, the NK₁ receptor antagonist, the solvent, benzalkonium chloride, and sodium edetate.

30. (Withdrawn) The inhalable solution or suspension according to claim 23, consisting essentially of the anticholinergic, the NK₁ receptor antagonist, the solvent, and benzalkonium chloride.

31. (Withdrawn) The inhalable solution or suspension according to claim 20, wherein the inhalable solution or suspension is a concentrate or a sterile ready-to-use inhalable solution or suspension.

32. – 33. (Canceled)


34. (Withdrawn) The propellant-containing inhalable aerosol according to claim 17, wherein the propellant gas is TG134a, TG227 or a mixture thereof.

35. (Currently Amended) A method of treatment of ~~a disease selected from the group consisting of asthma, chronic obstructive pulmonary disease, pulmonary hypertension, allergic rhinitis and non-allergic rhinitis~~, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 1.

36. (Canceled)

37. (Currently Amended) A method of treatment of ~~a disease selected from the group consisting of asthma, chronic obstructive pulmonary disease, pulmonary hypertension, allergic rhinitis and non-allergic rhinitis~~, comprising administering simultaneously or

sequentially to a mammal in need of such a treatment a therapeutically effective amount of a first pharmaceutical formulation comprising one or more anticholinergics of formula 1



wherein:

X^{-} is an anion with a single negative charge, or an enantiomer, mixture of the enantiomers, racemate, solvate, or hydrate thereof; and

a second pharmaceutical formulation comprising one or more NK_1 receptor antagonists or an enantiomer, mixture of the enantiomers, racemate, solvate, or hydrate thereof.